Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis
- 470 Downloads
Aminoglycoside (AG) therapy is a common cause of acute kidney injury (AKI) in cystic fibrosis (CF) patients. The aim of this study was to identify factors associated with AKI during intravenous AG courses in this population.
This was a matched case–control study utilizing two independent cohorts of hospitalized CF patients receiving ≥3 days of intravenous AG at Cincinnati Children’s Hospital Medical Center and Children’s of Alabama. All admissions with AKI (cases, N = 82) were matched to two randomly selected admissions without AKI (controls, N = 164) by center, gender, and age ±3 years of the case. AKI was defined as a 1.5-fold increase in the baseline serum creatinine (SCr) level or by an increase in SCr level of 0.3 mg/dL within 48 h. Admissions with AKI before day 4 or without at least weekly SCr monitoring were excluded from the analysis. Factors were compared between cases and controls using simple and multiple conditional logistic regression.
Multivariable analysis identified receipt of an AG within 90 days prior to admission, longer duration of AG therapy, low serum albumin, and receipt of trimethoprim/sulfamethoxazole as independent risk factors for developing AKI. Infection with Staphylococcus aureus diminished the odds of developing AKI.
This study identifies risk factors contributing to AG-associated AKI in CF patients. These findings can be used to anticipate high-risk scenarios and limit AKI in CF patients under clinical care.
KeywordsAcute renal failure Adverse drug events Antibiotics Drug-induced nephrotoxicity Pediatrics
Sources of funding
There was no direct funding for this study. Dr. Downes was supported by the National Institute of Child Health and Human Development of the National Institutes of Health under award number 5T32HD069054, Cincinnati Training Program in Pediatric Clinical and Developmental Pharmacology. Dr. Harris receives funding from the Cystic Fibrosis Foundation (HARRIS12Q0). Dr. Clancy receives grant support from the NIH (NHLBI-FOA-HL 12–035) and the Cystic Fibrosis Foundation (R457-CR11, AMIN09YO). Dr. Goldstein is supported in part by the Agency for Healthcare Research and Quality Center for Education and Research on Therapeutics grant (AHRQ CERT 1U19HS021114). Dr. Askenazi receives funding from the Pediatric and Infant Center for Acute Nephrology (PICAN) which is sponsored by Children’s of Alabama and the University of Alabama at Birmingham’s School of Medicine, Department of Pediatrics and Center for Clinical and Translational Science (CCTS). Funding for REDCap at CCHMC is provided by Center for Clinical and Translational Science and Training grant support (UL1-RR026314). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Conflict of interest
- 27.Elin RJ (2011) Appendix: Reference intervals and laboratory values. In: Goldman L, Schafer AI (eds) Goldman’s Cecil medicine, 24th edn. Saunders Elsevier, Philadelphia, pp 2558–2569Google Scholar
- 28.Arcara KM (2012) Blood chemistries and body fluids. In: Johns Hopkins Hospital, Arcara KM, Tschudy M (eds) The Harriet Lane handbook, 19th edn. Elsevier/Mosby, Philadelphia, pp 639–650Google Scholar
- 30.Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11:1–190Google Scholar
- 31.Lexicomp® (2009) Drug information handbook. Lexi-Comp, Inc., HudsonGoogle Scholar
- 37.Maki DG, Fox BC, Kuntz J, Sollinger HW, Belzer FO (1992) A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med 119:11–24PubMedGoogle Scholar